Clinical Characterisation of the Vascular Effects of Cis-platinum Based Chemotherapy in Patients With Testicular Cancer

Cardiovascular Diseases Clinical Trial

— VECTOR  

Official title:

Clinical Characterisation of the Vascular Effects of Cis-platinum Based Chemotherapy in Patients With Testicular Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03557177
• Other study ID #: GN15CA467
• Status: Completed
• Start date: September 1, 2016
• Est. completion date: July 1, 2018

Study information

• Verified date: November 2019
• Source: NHS Greater Glasgow and Clyde
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

incidence is increasing1,2. Whilst the prognosis is very good with the vast majority of patients cured with orchidectomy alone, those with high risk stage one non seminomatous germ cell cancer (NSCGT) or metastatic disease (NSCGT or seminoma) are treated by surgery followed by chemotherapy. Platinum based chemotherapy is associated with long-term cardiovascular sequelae.

Endothelial dysfunction is a key component of early atherogenesis and the later stages of obstructive atherosclerosis, plaque rupture and thrombus formation. Whilst endothelial toxic effects of BEP chemotherapy appear to be central in the pathophysiology of associated complications, abnormalities in endothelial function as assessed by measures of brachial artery flow-mediated dilatation (FMD) have not demonstrated a consistent effect over time. When assessed within ten weeks of platinum-based chemotherapy9, no change in FMD was observed whilst marked decreases are seen immediately following treatment11 and also one year following treatment12. Therefore, the time-course of endothelial vasomotor impairment remains incompletely defined in a single prospective cohort.

Description:

There remains an unmet need to identify a preventive treatment for patients with testicular cancer treated with platinum based chemotherapy to diminish the substantial risk of subsequent cardiovascular events. A future randomised trial of statin therapy in these patients is under consideration and results from this pilot study will inform its design.

Before moving towards interventional studies the proposed pilot study will enable a better understanding of the nature, time-course and dose-dependent effects of the mechanisms contributing to increased cardiovascular risk.

Single-centre, prospective pilot study assessing the cardiovascular effects of treatment with orchidectomy or orchidectomy plus cisplatin based chemotherapy for testicular cancer.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 36
• Est. completion date: July 1, 2018
• Est. primary completion date: July 1, 2018
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Histological diagnosis of stage 1 or IGCCCG5good or intermediate prognosis metastatic testicular/retroperitoneal germ cell cancer with treatment plan that includes orchidectomy or orchidectomy plus cisplatin based chemotherapy

• Aged between 18 and 65 years inclusive

Exclusion Criteria:

• Unable to provide written, informed consent

• Unable or unwilling to attend for investigations

• Current involvement in a clinical trial

• Anti-platelet therapy at time of enrolment

• Statin or other lipid-lowering therapy at time of enrolment

• Recreational drug use

• Ongoing inflammatory, infective or autoimmune disease

• Other malignant disease diagnosed in previous 5 years

• Previous venous or arterial thrombotic/thromboembolic event

Related Conditions & MeSH terms

• Cardiovascular Diseases
• Testicular Cancer
• Testicular Neoplasms

Locations

Country	Name	City	State
United Kingdom	Beatson West of Scotland Cancer Centre	Glasgow

Sponsors (2)

Lead Sponsor	Collaborator
NHS Greater Glasgow and Clyde	University of Glasgow

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in flow-mediated dilatation post cisplatin based chemotherapy	Maximum change in flow-mediated dilatation post cisplatin based chemotherapy	9 months
Secondary	Percentage change in circulating platelet monocyte aggregates post cisplatin based chemotherapy	Maximum change in percentage circulating platelet monocyte aggregates post cisplatin based chemotherapy	9 months